Frontiers in Pharmacology (Sep 2022)
Editorial: Cancer therapy: The challenge of handling a double-edged sword
- Kulmira Nurgali,
- Kulmira Nurgali,
- Kulmira Nurgali,
- John A. Rudd,
- John A. Rudd,
- Halina Was,
- Raquel Abalo,
- Raquel Abalo,
- Raquel Abalo,
- Raquel Abalo,
- Raquel Abalo
Affiliations
- Kulmira Nurgali
- Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia
- Kulmira Nurgali
- Department of Medicine Western Health, University of Melbourne, Melbourne, VIC, Australia
- Kulmira Nurgali
- Regenerative Medicine and Stem Cells Program, Australian Institute for Musculoskeletal Science (AIMSS), Melbourne, VIC, Australia
- John A. Rudd
- School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
- John A. Rudd
- The Laboratory Animal Services Centre, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
- Halina Was
- Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine, Warsaw, Poland
- Raquel Abalo
- Área de Farmacología y Nutrición, Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos (URJC), Alcorcón, Spain
- Raquel Abalo
- Unidad Asociada I+D+i del Instituto de Química Médica (IQM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
- Raquel Abalo
- High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, Alcorcón, Spain
- Raquel Abalo
- 0Grupo de Trabajo de Ciencias Básicas en Dolor y Analgesia de la Sociedad Española del Dolor, Madrid, Spain
- Raquel Abalo
- 1Grupo de Trabajo de Cannabinoides de la Sociedad Española del Dolor, Madrid, Spain
- DOI
- https://doi.org/10.3389/fphar.2022.1007762
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords